Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$9.93
-$0.14(-3.63%)
At close: 4:00 PM EST
$9.93
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$2.80 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)1.24M
Market Cap
$450.49M
Enterprise Value$353.65M
Total Cash (Recent Filing)$236.45M
Total Debt (Recent Filing)$33.76M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 18, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding60,795,210
10 Day Avg. Volume1,266,978
30 Day Avg. Volume1,240,783
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-408.37
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$30.00Price Target Upside202.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical/Regulatory MomentumPositive Phase 2/registrational readouts materially de-risk Kyverna’s lead program and strengthen its regulatory pathway. Over the medium term this raises the probability of approval, supports a clearer commercialization plan in rare neuroimmunology, and improves partner and investor confidence.
Balance Sheet StrengthVery low leverage and sizeable equity provide structural runway to advance clinical programs without heavy debt pressure. This reduces short-term refinancing risk, preserves strategic optionality for partnerships or licensing, and supports capital access while development milestones are pursued.
Senior Management AdditionsAppointing an experienced biopharma CFO strengthens financial leadership through the transition toward commercialization. His background should improve capital allocation, financing execution and investor communications—durable capabilities that support scaling, covenant management, and commercial readiness.
Bears Say
High Cash Burn / No RevenueSustained large cash burn with no revenue makes the company structurally dependent on external financing. Over several quarters this elevates dilution risk, constrains discretionary R&D and commercial investment, and forces milestone-driven funding paths that can alter strategic choices.
Widening LossesAccelerating net losses reflect heavier R&D and operating spend without offsetting revenue, driving deeply negative returns on equity. Persistently widening losses weaken internal funding capacity and heighten reliance on successful clinical outcomes to justify future capital raises.
Financing Covenants & Conditional TranchesThe amended term loan links future tranches to revenue and clinical milestones and imposes minimum revenue covenants beginning as early as mid-2027. This structurally reduces financial flexibility and could force operational or financing actions if milestones or revenue timing fall short.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $2.80 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $450.49M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 23 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.752 by $0.092.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.68.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,795,210 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.752. Following the earnings report the stock price went up 5.376%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (202.11% Upside)
$30.00 (202.11% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 2.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.39%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$30.00
▲(202.11% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
23.23% Insiders
5.87% Mutual Funds
0.33% Other Institutional Investors
61.60% Public Companies and
Individual Investors